Pulse cyclophosphamide treatment for severe refractory cutaneous lupus erythematosus

Lupus

Volumn 19, Issue 6, 2010, Pages 744-747

  Raptopoulou, A ^a   Linardakis, C ^a   Sidiropoulos, P ^a   Kritikos, H D ^a   Boumpas, D T ^a  

^a UNIVERSITY OF CRETE   (Greece)

Author keywords

Cutaneous lupus; Cyclophosphamide; Subacute lupus erythematosus

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; LEUPRORELIN; METHYLPREDNISOLONE; PREDNISOLONE; THALIDOMIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GONADAL DISEASE; HAIR LOSS; HUMAN; LOW DRUG DOSE; MAINTENANCE THERAPY; NAUSEA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REMISSION; SIDE EFFECT; SKIN LUPUS ERYTHEMATOSUS; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING;

ADULT; ANTIRHEUMATIC AGENTS; AZATHIOPRINE; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, CUTANEOUS; MIDDLE AGED; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 77951240333     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203309358601     Document Type: Article

References (15)

1. Laman SD, Provost TT Cutaneous manifestations of lupus erythematosus. Rheum Dis Clin North Am 1994 ; 20: 195-212.
2. Boumpas DT, Fessler B., Austin H., Balow JE, Klippel JH, Lockshin MD Systemic lupus erythematosus: emerging concepts: Part 2: Dermatologic and joint disease, the antiphospholipid syndrome, pregnancy and hormonal therapy, morbidity and mortality, and pathogenesis. Ann Intern Med 1995 ; 123: 42-53.
3. Duna FG, Cash JM Treatment of refractory cutaneous lupus erythematosus. Rheum Dis Clin North Am 1995 ; 21: 99-115.
4. Ting WW, Sontheimer RD Local therapy for cutaneous and systemic lupus erythematosus: practical and theoretical considerations. Lupus 2001 ; 10: 171-184. (Pubitemid 32410073)
5. Jessop S., Whitelas D., Jordaan F. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev 2001 ; 1: CD002954.
6. Callen JP Management of skin disease in patients with lupus erythematosus. Best Pract Res Clin Rheumatol 2002 ; 16: 245-260.
7. Cuadrado MJ, Karim Y., Sanna G., Smith E., Khamashta MA, Hughes GR Thalidomide for the treatment of resistant cutaneous lupus: Efficacy and safety of different therapeutic regimens. Am J Med 2005 ; 118: 246-250. (Pubitemid 40312635)
8. Tassioulas I., Boumpas DT Clinical features and treatment of systemic lupus erythematosus. In Kelley's Textbook of Rheumatology, 8 th edn. Philadelphia, PA: Saunders-Elsevier ; 2009. p. 1263-1300.
9. Wenzel J., Brähler S., Bauer R., Bieber T., Tüting T. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. Br J Dermatol 2005 ; 153: 157-162. (Pubitemid 41044542)
10. Schanz S., Ulmer A., Rassner G., Fierlbeck G. Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil. Br J Dermatol 2002 ; 147: 174-178. (Pubitemid 34779458)
11. Callen JP, Spencer LV, Burruss JB, Holtman J. Azathioprine: an effective, corticosteroids-sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leucocytoclastic vasculitis. Arch Dermatol 1991 ; 127: 515-522.
12. Takada K., Illei GG, Boumpas DT Cyclophosphamide for the treatment of systemic lupus erythematosus. Lupus 2001 ; 10: 154-161. (Pubitemid 32410070)
13. Albrecht J., Taylor L., Berlin JA, et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): An outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 2005 ; 125: 889-894.
14. Raptopoulou A., Sidiropoulos P., Boumpas D. Ovarian failure and strategies for fertility preservation in patients with systemic lupus erythematosus. Lupus 2004 ; 13: 887-890. (Pubitemid 39664945)
15. Basra MK, Shahrukh M. Burden of skin diseases. Expert Rev Pharmacoecon Outcomes Res 2009 ; 9: 271-283.